Promising results reported with combination immunotherapy for glioblastoma

A novel approach to immunotherapy may improve outcomes in patients with newly diagnosed glioblastoma (ND-GBM), new data suggest.

“Despite decades of research, no significant change in survival has been made in GBM”, according to Dr David Reardon of the Dana-Farber Cancer Institute in Boston, Massachusetts, USA. “And despite advances with immune checkpoint inhibitors in other cancers, there has been no significant improvement in survival compared to historical controls in ND-GBM.”